Efficient in vitro screening for drug combinations: The TEVA model
Efficient in vitro screening for drug combinations: The TEVA model
SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in patients with advanced metastatic NSCLC
Oncobox, RNA sequencing and molecular pathway analysis-base system for prescription of target drugs to advanced cancer patients
The value of personalised medicines for healthcare systems in Europe
Decision support for precision oncology: Evolving from monotherapy to genomically informed combinations
CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
Systems immunology in immuno-oncology
Highlights from WIN 2019
Innovation in clinical trials: WINTHER trial
Data sharing and system interoperability: The Osiris French Program
RET inhibition in RET aberrant cancers
Goals of the WIN Consortium